G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?

2018/01/03 by Krishna Sriram, Paul A. Insel · 16 citations
Biochemistry, Genetics and Molecular Biology · Computer Science · Pharmacology, Toxicology and Pharmaceutics · #Receptor Mechanisms and Signaling #Computational Drug Discovery Methods #Pharmacogenetics and Drug Metabolism

paper · pdf · doi:10.1124/mol.117.111062

Cited by

• Design of allosteric modulators that change GPCR G protein subtype selectivity
• Nanodomain cAMP signaling in cardiac pathophysiology: potential for developing targeted therapeutic interventions
• Advantages and shortcomings of cell-based electrical impedance measurements as a GPCR drug discovery tool
• How accurately can one predict drug binding modes using AlphaFold models?
• Chemical biology approaches to resolve the subcellular GPCR signaling landscape
• Biased signaling in drug discovery and precision medicine
• Using AlphaFold and Experimental Structures for the Prediction of the Structure and Binding Affinities of GPCR Complexes via Induced Fit Docking and Free Energy Perturbation
• Ghrelin receptor signaling in health and disease: a biased view
• Cell-Free Systems and Their Importance in the Study of Membrane Proteins
• A positive allosteric modulator of the β1AR with antagonist activity for catecholaminergic polymorphic ventricular tachycardia
• Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery
• Physiological functions and structural features of Gα12/13 proteins
• The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
• An amphipol‐stabilized multi‐pass transmembrane protein as an immunogen to generate mouse memory B cells against native VMAT 2
• Membrane Protein Complexity Revealed Through Native Mass Spectrometry
• Mechanisms governing GPCR anterograde transport